These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7581527)

  • 1. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
    Bercovich E; Deriu M; Manferrari F; Irianni G
    Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
    Kälble T; Beer M; Mendoza E; Ikinger U; Link M; Reichert HE; Frangenheim T; Klein E; Fabricius PG
    Urologe A; 1994 Mar; 33(2):133-7. PubMed ID: 8178407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
    Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
    Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
    Joudi FN; Smith BJ; O'Donnell MA;
    Urol Oncol; 2006; 24(4):344-8. PubMed ID: 16818189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intravesical BCG vaccine in bladder cancer].
    Beisland HO; Sander S
    Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of superficial bladder tumors with intravesical BCG].
    Miskowiak J; Jensen JS
    Ugeskr Laeger; 1992 Mar; 154(10):640-3. PubMed ID: 1542971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical immunotherapy with BCG vaccine in superficial carcinoma of the urinary bladder].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Oct; 76(10):482-5. PubMed ID: 9471737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
    Wen R; Zhou G; Xie S; Lian B; Sun X; Chen J
    Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):247-8. PubMed ID: 11825381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the optimal treatment strategy for T1 bladder tumors?
    Babjuk M
    Eur Urol; 2010 Jan; 57(1):32-4. PubMed ID: 19846251
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
    Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
    Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up.
    Mohanty NK; Malhotra V; Nayak RL; Arora RP
    J Chemother; 2002 Apr; 14(2):194-7. PubMed ID: 12017377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?].
    Mack D; Frick J
    Urologe A; 1992 Mar; 31(2):88-90. PubMed ID: 1561732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG in the management of superficial bladder cancer.
    Guinan P; Richardson C; Hanna M; Rubenstein M
    Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.